CClinicalTrials.gg
CompletedNCT03993028Updated Jun 20, 2019

The Effects of Sex, Body Mass Index, Day-to-Day Subject Variability for the ProLung Test and Variability of a Single Device When Volume-Averaged Thoracic Bioconductance is Measured With the ProLung Test

An observational study in Healthy Volunteers, sponsored by Fresh Medical Laboratories. Completed. Open to participants aged 35 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-20.

Sponsored by Fresh Medical Laboratories · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
35 Years to 70 Years
Sex
All
01

Study summary

Assess the repeatability of the ProLung Test

Read the detailed description

This repeatability study of the ProLung Test enrolled sixty subjects, 30 male and 30 female, half of each sex with a body mass index (BMI) of 30 or more, and half with a BMI of 28 or less. Each subject was scanned twice on Day One and twice on Day Two. All scans were done by the same operator on the same device. Fifty-nine subjects produced evaluable data. Four models (algorithms) were tested.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Fresh Medical Laboratories is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy Volunteers

Inclusion criteria

  • Age 35 to 70 years
  • Able to understand and fulfill all requirements of this protocol
  • Provide signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Pacemaker or other implanted medical device
  • Current life-threatening medical condition
  • Current or recent use of systemic corticosteroids
  • Pregnant or lactating
  • Unusually strenuous exercise within previous 24 hours
  • Current abuse of alcohol or drugs
  • Medical or anatomical condition that precludes testing of all 62 measurement points
  • Other condition or reason at the discretion of the Principal Investigator or medical monitor
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Quantify EPN Scanner variability in transcutaneous volume-averaged thoracic bio-conductance when measured twice on the same subjects by the same operator on a single same day using the same EPN Scanner

    The null hypothesis is that same-day variability has no effect on scan results (i.e. when scanned twice on the same day).

    Time frame: 1 day

  2. Quantify day-to-day within-subject variability when the same operator uses the same EPN Scanner on the same subjects to measure transcutaneous volume-averaged thoracic bio-conductance on two different days within one week.

    The null hypothesis is that day-to-day variability has no effect on scan results (i.e. when scanned twice on separate days).

    Time frame: 1 week

  3. Effects of BMI and Sex on transcutaneous volume-averaged thoracic bio-conductance

    The null hypothesis is that BMI has no effect on scan results. The null hypothesis is that sex has no effect on scan results.

    Time frame: 1 week

  4. Number of participants with device-related adverse events from thoracic bio-conductance measurement.

    time to complete scan.

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03993028
Lead sponsor
Fresh Medical Laboratories
Responsible party
Sponsor
First posted
Jun 20, 2019
Start date
Nov 20, 2015
Primary completion
Nov 21, 2018
Completion
Nov 21, 2018
Last update
Jun 20, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion